Tag Archives: Organon

Organon (OGN) 24Q1 Update

24Q1 revenues were $1.622 billion, up 5.5% year-over-year, but up 7% at constant currency.  GAAP diluted EPS was $0.78, above 23Q1’s $0.69 and my estimate of $0.77.  Non-GAAP EPS of $1.22 was above last year’s $1.08 and also above my … Continue reading

Posted in Health Care, OGN | Tagged | Leave a comment

Organon (OGN) 23Q3 Update

23Q3 revenues were $1.52 billion, down 1.2% YOY and also down 1% at constant currency.  GAAP diluted EPS was $0.23, compared with 22Q3’s $0.90 and my estimate of $0.74.  Non-GAAP EPS of $0.87 was below last year’s $1.32 and my … Continue reading

Posted in Health Care, OGN | Tagged , | Comments Off on Organon (OGN) 23Q3 Update

Organon & Co. (OGN) 23Q2 Update

23Q2 revenues were $1.61 billion, up 1.5% YOY and up 4% at constant currency.  GAAP diluted EPS was $0.95, better than 22Q2’s $0.92 and above my estimate of $0.87.  Non-GAAP EPS of $1.31 was higher than last year’s $1.25 and … Continue reading

Posted in Health Care, OGN | Tagged , | Comments Off on Organon & Co. (OGN) 23Q2 Update

Organon & Co. 23Q1 Update

23Q1 revenues were $1.538 billion, down 1.9% year-over-year, but up 3% at constant currency.  GAAP diluted EPS was $0.69, below 22Q1’s $1.36 and below my estimate of $0.88.  Non-GAAP EPS of $1.08 was below last year’s $1.65 and also below … Continue reading

Posted in Health Care, OGN | Tagged , | Comments Off on Organon & Co. 23Q1 Update

Organon & Co (OGN) 22Q4 Update

22Q4 revenues were $1.485 billion, down 7.4% year-over-year, but up 1% at constant currency.  GAAP diluted EPS was $0.43, below 21Q4’s $0.80 and below my estimate of $0.54.  Non-GAAP EPS of $0.82 was below last year’s $1.18 and a penny … Continue reading

Posted in Health Care, OGN | Tagged , | Comments Off on Organon & Co (OGN) 22Q4 Update

Organon & Co. (OGN) 22Q3 Update

22Q3 revenues were $1.537 billion, down 3.9% year-over-year, but up 3% at constant currency.  GAAP diluted EPS was $0.92, below 21Q3’s $1.27, but above my estimate of $0.82.  Non-GAAP EPS of $1.36 was below last year’s $1.61, but also above … Continue reading

Posted in Health Care, OGN | Tagged , | Comments Off on Organon & Co. (OGN) 22Q3 Update

Organon & Co (OGN) 22Q2 Update

22Q2 revenues of $1.585 billion were flat year-over-year, but up 5% at constant currency.  GAAP EPS of $0.92, was below 21Q2’s $1.68 and also below my $1.11 estimate.  Non-GAAP EPS of $1.25 was below last year’s $1.72 and also below … Continue reading

Posted in Health Care, OGN | Tagged , | Comments Off on Organon & Co (OGN) 22Q2 Update

Organon 21Q3 Update

Organon reported 21Q3 GAAP EPS of $1.38 which exceeded my estimate of $1.31.  Revenues were in line with my estimates and operating costs were lower, except for a $25 million increase associated with the acquisition of in-process research & development.

Posted in Health Care, OGN | Tagged , | Comments Off on Organon 21Q3 Update

Organon (OGN) 21Q2 Update

21Q2 Performance in Line with Expectations; Raising Performance Rating and Lowering Price Target 21Q2 GAAP EPS of $1.68 was lower than 20Q2’s $2.14.  Although sales increased 4.5% to $1.6 billion, costs were higher as a result of new tolling arrangements … Continue reading

Posted in Health Care, OGN | Tagged , | Comments Off on Organon (OGN) 21Q2 Update

Assessing the Impact of the Organon Spin-Off on Merck

Merck is progressing toward the spin-off of its subsidiary, Organon & Co., which is expected to be completed by the end of the June.  Organon will include Merck’s women’s health products, biosimilars and certain established brands, most of which have … Continue reading

Posted in Health Care, MRK, OGN | Tagged , , , | Comments Off on Assessing the Impact of the Organon Spin-Off on Merck

Merck Spin-Off of Organon Targeted for 21Q2

In recent weeks, Merck has been following through on its plan to spin-off its subsidiary, Organon & Co., to shareholders.  On March 17, it filed its Form 10 registration statement related to the transaction.  On March 24, it posted on … Continue reading

Posted in Health Care, MRK, OGN | Tagged , , | Comments Off on Merck Spin-Off of Organon Targeted for 21Q2